The U.S Food and Drug Administration (FDA) has approved a new drug combination for men with metastatic, castration-resistant prostate cancer (mCRPC) and certain DNA repair gene mutations, widening treatment options for this large patient population.
The androgen-receptor inhibitor enzalutamide plus the PARP inhibitor talazoparib can now be used as first-line treatment for mCRPC patients who have homologous recombination repair (HRR) gene alterations.
#MetastaticProstateCancer.
A new combination therapy for for metastatic prostate cancer that includes an already approved breast cancer drug was just approved by the FDA last month on June 20. It has many excited.
The FDA has approved a new drug combination therapy for metastatic castration-resistant prostate cancer and DNA repair gene mutations.
Leave a reply